The SME IPO market in India has been buzzing with activity in 2025, with several niche companies tapping the public markets to fuel their growth ambitions. Among the latest entrants is Snehaa Organics, a Hyderabad-based enterprise specialising in solvent recovery and recycling.
In this Snehaa Organics IPO Review, we explore the business model, operational efficiency & everything you should know about the company before investing. The company is set to launch its IPO on NSE EMERGE between 29 Aug – 2 Sep 2025, with a price band of INR 115–122 per share. The issue comprises a fresh offer of 26.79 lakh shares, aggregating up to INR 32.68 crore, aimed at supporting its expansion and strengthening its financial position.
Company Overview
Snehaa Organics has evolved rapidly over the past seven years. It began operations in 2017 as a partnership firm under the name M/s Snehaa Pharma Chemicals. In 2019, the partnership underwent a reconstitution, bringing in new promoters including Mr. Ramasubba Reddy Nandigala, Mrs. Venkata Lakshmi Nandigala, Mr. Nandigala Venkata Sai Harish, and Rama Subba Reddy HUF. This shift in ownership marked a turning point, as the firm began focusing on structured solvent recovery as a scalable business model.
By July 2022, Snehaa transitioned into a private limited company, Snehaa Organics, and within just over two years, in January 2025, it was converted into a public limited company to facilitate broader capital access.
Snehaa Organics IPO Review: Business Model
Snehaa Organics business model revolves around providing sustainable solvent recovery and recycling solutions for industries, primarily pharmaceuticals and speciality chemicals. The company acts as a crucial link in the circular economy by enabling clients to reuse solvents, thereby reducing costs and environmental impact.
At its core, the business runs on three operational pillars:
- Solvent Recovery (Job Work): Industrial clients send spent solvents to Snehaa’s facility. Using advanced distillation technology and strict quality control, the company purifies and returns solvents to the client as per agreed recovery terms. This ensures steady recurring business with minimal raw material risk.
- Distillation & Sale of Recovered Solvents: Excess solvents recovered during job work — over and above client commitments — are retained and marketed by Snehaa. This allows the company to capture additional value from the same process.
- Direct Solvent Trading: Snehaa also sources solvents from domestic suppliers, tests quality in-house, and sells them to industry buyers. This supplements its core recycling business and helps in maintaining customer relationships across cycles.
What makes this model resilient is the integration of recovery, purification, and trading into one cycle. The company manages procurement, processing, quality testing, and logistics internally — ensuring end-to-end control, reduced dependency on external factors, and higher efficiency.
In short, Snehaa Organics business model is designed to:
- Balance steady contract-driven work with market-driven trading opportunities.
- Reduce industrial solvent waste.
- Offer cost savings and compliance benefits to pharma clients.
- Monetise every stage of the solvent lifecycle.
Operational Infrastructure
The company’s manufacturing strength lies in its facility at IDA Bollaram, Hyderabad, spread across 3,300 square feet. This proximity to India’s largest bulk drug cluster provides easy access to both suppliers and customers.
Over the years, Snehaa Organics has increased its installed capacity from 7,200 MTS in FY23 to 7,920 MTS in FY24, and further to 8,640 MTS in FY25. What is striking is not just the increase in installed capacity but also the high utilisation levels: 82.22% in FY23, 81.30% in FY24, and 88.15% in FY25.
Snehaa Organics IPO Analysis: Financials
Over the last three years, Snehaa Organics has demonstrated consistent revenue growth, margin expansion, and operational efficiency. Below is a consolidated snapshot of its financial performance:
| Particulars | FY23 | FY24 | FY25 | Remarks |
|---|---|---|---|---|
| Revenue | 13.65 | 23.72 | 26.22 | ~38% CAGR (FY23–FY25); steady topline growth |
| Expenses | 9.92 | 18.78 | 16.48 | Better cost control visible in FY25 despite scaling operations |
| Net Profit (PAT) | 2.78 | 3.66 | 7.34 | Profit more than doubled in FY25 |
| Net Margin (%) | 20.3% | 15.4% | 28.0% | Strong margin rebound in FY25 |
| Debt/Equity | – | 4.29 | 4.62 | Leverage remains high but appears productively deployed |
| Return on Net Worth (RONW) | – | 49.20% | 49.66% | Among the highest in SME IPOs |
| Return on Capital Employed (ROCE) | – | 50.33% | 46.70% | Sustained efficiency in capital deployment |
| EBITDA Margin | – | 30.54% | 24.58% | Margins moderated but remain healthy |
| Capacity Utilization | 82.22% | 81.30% | 88.15% | Reflects strong demand and operational efficiency |
Snehaa Organics IPO Review: Revenue Streams
Snehaa Organics revenue streams are based on three pillars – Job Work (contract distillation), Sale of Distilled Products, and Direct Trading of Solvents. Their contribution to topline has shifted over time, with distilled products increasingly driving margins.
| Revenue Source | FY23 | FY24 | FY25 | % Share (FY25) |
|---|---|---|---|---|
| Job Work (Distillation Services) | 4.94 | 7.57 | 9.18 | 35.0% |
| Sale of Distilled Products | 7.45 | 12.65 | 11.98 | 45.7% |
| Direct Trading of Solvents | 1.26 | 3.50 | 5.06 | 19.3% |
| Total Revenue | 13.65 | 23.72 | 26.22 | 100% |
Insights:
- Distilled products remain the largest contributor (46%), underscoring Snehaa’s operational edge in recovering solvents beyond client commitments.
- Job work provides a steady recurring income and anchors revenue stability.
- Direct trading, while lower margin, has scaled rapidly (4x from FY23 to FY25), helping diversify the topline.
- Importantly, this multi-stream structure reduces dependence on any single business line, balancing stability and growth.
Geographic Revenue Mix
Revenue remains largely concentrated in Telangana, thanks to Hyderabad’s position as India’s bulk drug capital. However, new states are beginning to contribute.
| Geography (INR Cr) | FY23 | FY24 | FY25 | % Share (FY25) |
|---|---|---|---|---|
| Telangana | 12.74 | 19.33 | 23.60 | 90%+ |
| Andhra Pradesh | 0.45 | 1.89 | 0.42 | 1.6% |
| Maharashtra | – | 0.68 | 0.51 | 2.0% |
| West Bengal / Punjab / Others | 0.46 | 1.43 | 1.22 | 4–5% |
| Total Revenue | 13.65 | 23.72 | 26.22 | 100% |
Insights:
- Telangana dominates, but the company has begun tapping Maharashtra, West Bengal, and Punjab in FY24–25.
- Andhra Pradesh’s share has declined, showing the need for balanced expansion.
- Future growth will hinge on geographic diversification, reducing dependency on a single cluster.
Snehaa Organics IPO Review: SWOT Analysis
| Strengths 1. Modern infrastructure (60 KL kettles, 27 KL reactors) and high utilisation (~88%). 2. Strategic Hyderabad location – proximity to pharma hubs. 3. Strong reputation in the pharma sector; promoters with decade-long industry experience. | Weaknesses 1. High dependence on Telangana for revenue. 2. Leverage-heavy balance sheet (Debt/Equity 4.62). 3. Operational complexity due to handling diverse solvents and strict compliance requirements. |
| Opportunities 1. Expansion into new Indian states and export markets. 2. Product diversification into Acetonitrile, THF, and Tertiary Butyl Alcohol (2TB) – high-value pharma solvents. 3. Potential forward integration with pharma customers. | Threats 1. Regulatory changes around effluent disposal or solvent handling. 2. Raw material price volatility (Acetonitrile, THF, etc.). 3. Intense competition in SME recycling and solvent trade. |
Final Words
Snehaa Organics stands out in the SME IPO space for its robust fundamentals, high return ratios, and sustainable business model. The company has demonstrated the ability to scale operations while maintaining profitability. However, high leverage and geographic concentration remain key risks.
At a valuation of ~12x earnings, the IPO offers a compelling risk-reward for investors seeking exposure to the pharma-linked recycling theme. Short-term investors may benefit from a strong listing gain, while long-term investors should track how effectively the company reduces debt and expands beyond Telangana.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.